ProBioGen secures extended GMP authorisation for viral manufacturing facility

pharmafile.com | November 16, 2026 | News story | |  GMP, Immunology, Infections and infestations, manufacturing, pharmaceutical 

ProBioGen has secured extended manufacturing authorisation and an updated Good Manufacturing Practice (GMP) certificate for its dedicated viral manufacturing facility in Berlin, allowing it to manufacture sterile biological drug substances and investigational medicinal products, including viral vectors and vaccines.

Granted by the Berlin State Office for Health and Social Affairs (Lageso), the authorisation extends the company’s existing GMP manufacturing services for therapeutic proteins into viral products and advanced therapy medicinal products (ATMPs).

The facility has drug substance production capacity of up to 200 litres, alongside in-house aseptic filling and quality control laboratories. Its integrated capabilities are intended to support customers from process development through GMP manufacturing and filling for clinical supply.

Advertisement

Qualification included three successful aseptic process simulations in accordance with EU GMP Annex 1 requirements for sterile medicinal products. The facility uses restricted access barrier system (RABS) technology for drug product filling and incorporates filter integrity testing into its contamination-control procedures.

ProBioGen will also manufacture GMP drug substance for a Bundibugyo ebolavirus vaccine programme led by Egypt-based Minapharm. The candidate uses ProBioGen’s proprietary MVA-CR19 platform and is being advanced towards clinical evaluation, with Minapharm responsible for commercial drug product manufacturing.

The authorisation also provides a foundation for ProBioGen’s planned role operating a future GMP facility at the Berlin Center for Gene and Cell Therapies, which is currently under construction.

Related Content

Digital platform cuts pharmaceutical quality-record approval times by up to 90%

A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …

Sterling doubles ADC manufacturing capacity at Welsh facility

Sterling Pharma Solutions has completed a multi-million-pound expansion of its dedicated bioconjugation facility in Deeside, …

Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster

By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …

The Gateway to Local Adoption Series

Latest content